DNTH
Dianthus Therapeutics, Inc.
Industry
Biotechnology
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Loading...
Open
23.08
Mkt cap
705M
Volume
112K
High
23.88
P/E Ratio
3.30
52-wk high
33.77
Low
22.94
Div yield
N/A
52-wk low
6.58

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.